



| | |
|------------------|---|
| Title | Resistant maltodextrin or fructooligosaccharides promotes GLP-1 production in male rats fed a high-fat and high-sucrose diet, and partially reduces energy intake and adiposity |
| Author(s) | Hira, Tohru; Suto, Ryoya; Kishimoto, Yuka et al. |
| Citation | European Journal of Nutrition, 57(3), 965-979 https://doi.org/10.1007/s00394-017-1381-7 |
| Issue Date | 2017 |
| Doc URL | https://hdl.handle.net/2115/85305 |
| Rights | The final publication is available at link.springer.com |
| Type | journal article |
| File Information | Eur J Nutr 57_965.pdf |



1 **TITLE**

2 Resistant maltodextrin or fructooligosaccharides promotes GLP-1 production in male rats fed a
3 high-fat and high-sucrose diet, and partially reduces energy intake and adiposity

4 **AUTHORS**

5 Tohru Hira¹, Ryoya Suto², Yuka Kishimoto³, Sumiko Kanahori³, Hiroshi Hara¹

6 **AFFILIATIONS**

7 ¹ Research Faculty of Agriculture, Hokkaido University, Sapporo, JAPAN

8 ² Graduate School of Agriculture, Hokkaido University, Sapporo, JAPAN

9 ³ Research & Development, Matsutani Chemical Industry Co.,Ltd., Itami, Hyogo, JAPAN

10 **CORRESPONDING AUTHOR**

11 Tohru Hira

12 Laboratory of Nutritional Biochemistry, Research Faculty of Agriculture, Hokkaido University,
13 Kita-9, Nishi-9, Kita-ku, Sapporo 060-8589, Japan

14 Tel & Fax: +81-11-706-2811

15 Email: hira@chem.agr.hokudai.ac.jp

16 **RUNNING TITLE:** Increasing GLP-1 against diet-induced obesity

17

18 **Abbreviations:** HFS: High-fat and high-sucrose, GLP-1: Glucagon-like peptide-1, RMD:

19 Resistant maltodextrin, FOS: Fructooligosaccharides, GIP: Glucose-dependent insulinotropic

20 polypeptide, OGTT: Oral glucose tolerance test, PYY: Peptide YY, DPP-IV: Dipeptidyl peptidase-

21 IV, SCFA: Short chain fatty acid

22

23 **ABSTRACT**

24 Purpose

25 Increasing secretion and production of glucagon-like peptide-1 (GLP-1) by continuous
26 ingestion of certain food components has been expected to prevent glucose intolerance and
27 obesity. In this study, we examined whether a physiological dose (5% weight in diet) of digestion-
28 resistant maltodextrin (RMD) has a GLP-1-promoting effect in rats fed a high-fat and high-
29 sucrose (HFS) diet.

30 Methods

31 Rats were fed a control diet or the HFS (30% fat, 40% sucrose wt/wt) diet supplemented with
32 5% RMD or fructooligosaccharides (FOS) for 8 weeks or for 8 days in separated experiments.
33 Glucose tolerance, energy intake, plasma and tissue GLP-1 concentrations, and cecal short chain
34 fatty acids concentrations were assessed.

35 Results

36 After 4 weeks feeding, HFS-fed rats had significantly higher glycemic response to oral glucose
37 than control rats, but rats fed HFS+RMD/FOS did not (approx. 50% reduction vs HFS rats).
38 HFS+RMD/FOS-fed rats had higher GLP-1 responses (~2-fold) to oral glucose, than control rats.
39 After 8 weeks, visceral adipose tissue weight was significantly higher in HFS-fed rats than control
40 rats, while HFS+RMD/FOS rats had a trend of reduced gain (~50%) of the tissue weight. GLP-1
41 contents and luminal propionate concentrations in the large intestine increased (> 2-fold) by
42 adding RMD/FOS to HFS. Eight days feeding of RMD/FOS-supplemented diets reduced energy
43 intake (~10%) and enhanced cecal GLP-1 production (~2-fold), compared to HFS diet.

44 Conclusions

45 The physiological dose of a prebiotic fiber promptly (within 8 days) promotes GLP-1
46 production in rats fed an obesogenic diet, which would help to prevent excess energy intake and
47 fat accumulation.

48

49 **KEY WORDS:** Resistant maltodextrin; Fructooligosaccharides; Glucagon-like peptide-1; High-fat
50 and high-sucrose diet; Appetite; Adiposity.

51

52 **INTRODUCTION**

53 In recent years, glucagon-like peptide-1 (GLP-1), an incretin hormone, has received much
54 attention in association with glucose homeostasis. Besides the incretin effect, GLP-1 released from
55 enteroendocrine L cells has multiple other functions [1, 2], including pancreatic beta-cell
56 protection/proliferation, satiety induction, and gastric emptying suppression, as well as
57 cardioprotective and neuroprotective effects. Recently, incretin "enhancers" such as GLP-1 receptor
58 agonists and dipeptidyl peptidase-IV (DPP-IV) inhibitors have been widely and effectively used for
59 the treatment of type 2 diabetes [3], but effective "GLP-1 releasers" have not yet been developed for
60 therapeutic use. Increasing endogenous production and secretion of GLP-1 is thought to be a
61 promising strategy for the improvement of glucose tolerance owing to its insulinotropic (incretin)
62 effect; however, the concept has not been sufficiently proven.

63 GLP-1 secretion is stimulated by luminal macronutrients such as glucose, fatty acids, peptides,
64 and amino acids [4]. Several studies demonstrated that nutrient-induced GLP-1 release is effective
65 in attenuating glycemic responses in animals [5, 6] and humans [7, 8]. Further, stimulation of GLP-
66 1 secretion by non-absorbable compounds would be attractive because of their relatively long-
67 acting property throughout the intestinal lumen and less possibility for unexpected side effects after
68 absorption into the circulation. We recently demonstrated that a water-soluble prebiotic fiber,

69 digestion-resistant maltodextrin (RMD, contains 90% soluble dietary fiber), stimulated GLP-1
70 secretion after a single oral administration in rats [9]. Furthermore, continuous feeding of a diet
71 containing 5% RMD increased the plasma GLP-1 concentration and cecal GLP-1 content, together
72 with the improvement of glucose tolerance in normal rats.

73 The suppressive effects of prebiotic fibers such as RMD, oligofructose, inulin, and resistant
74 starch on obesity, hyperglycemia, dyslipidemia, and fat accumulation have been demonstrated
75 previously in animal and human studies [10-16]. Such effects of fermentable fibers can be mainly
76 explained by their ability to modify gut microbiota composition, increase short-chain fatty acid
77 production, and increase the secretion of gut hormones such as GLP-1 and peptide YY (PYY).
78 Although effects of RMD to attenuate glucose and insulin responses [16, 17], to reduce body fat
79 [16, 18], to increase satiety [19] and to promote GLP-1 [9] have separately been reported in
80 different experimental models, the effect of RMD on GLP-1 secretion and production has not been
81 clarified in the model during the development of diet-induced obesity.

82 In the present study we examined the hypothesis that the promoting effect of RMD on the
83 secretion and production of GLP-1 could be exerted in rats fed a high-fat and high-sucrose diet as
84 an obesogenic diet, and whether the effect would contribute to protection against glucose
85 intolerance, fat accumulation, and excess energy intake. In contrast to the majority of animal studies
86 employing more than 10% (w/w) dose of various prebiotic fibers such as inulin, oligofructose,
87 resistant starch, pectin, guar-gum, etc. [10-12, 15, 20-22], we examined a 5% (w/w) dose of RMD
88 and fructooligosaccharides (FOS) added to a diet because the 10% dose is relatively high
89 considering the recommended dose of dietary fiber (14 g/1,000 kcal, 20-38 g/day) in humans [23,
90 24, 25]. In experiment 1, rats were fed a control diet or high-fat and high-sucrose (HFS) diet
91 supplemented with a physiological dose (5%) of RMD or FOS for 8 weeks. Oral glucose tolerance
92 tests (OGTTs) were performed during the experimental period, and secretion and production of

93 GLP-1 were evaluated. In experiment 2, we monitored the energy intake daily for 8 days and then
94 collected blood and tissue samples to examine the promoting effects of the RMD/FOS-
95 supplemented diets on GLP-1 levels and satiety.

96

97

98 **MATERIALS AND METHODS**

99 **Animals and diets**

100 Male Sprague–Dawley rats (5-week-old, n=32 for experiment 1, n=28 for experiment 2) were
101 purchased from Japan SLC, Inc. (Shizuoka, Japan) and were fed an American Institute of Nutrition
102 (AIN)-93G-based diet [26] for a one-week acclimation period. Each rat was individually housed in
103 a separate cage and had free access to the diet and water, except for the days preceding the glucose
104 tolerance test and killing. The experiment was performed in a temperature-controlled room
105 maintained at 22 ± 2 °C with a 12 h light/12 h dark cycle (08.00 a.m.–20.00 p.m. light period). Rats
106 were divided into four groups (n=7 or 8 in each group) and fed the AIN-93G diet (control), HFS
107 diet (30% fat and 40% sucrose, wt/wt), or HFS diet in which cellulose was replaced with either
108 RMD (Fibersol-2; Matsutani Chemical Industry Co., Hyogo, Japan) or FOS (Meiologo-P; Meiji Co.,
109 Ltd., Tokyo, Japan) (Table 1) for 8 weeks (experiment 1) or 8 days (experiment 2). The digestion
110 resistant component in HDS+RMD diet is estimated at 4.5% by weight. In experiment 1, OGTTs
111 were conducted after 4 and 7 weeks of feeding the test diets, and the rats were fed the test diets for
112 further one week. After 8 weeks of test diet feeding and overnight fasting (16–20 hours), rats were
113 euthanized for tissue and blood sampling. Body weight and food intake were measured every 1–2
114 days. In experiment 2, the rats were fed the test diets for 8 days and euthanized on day 9 after
115 overnight fasting (16–20 hours). Food intake was measured daily in the morning (8–9 a.m.) and
116 evening (7–8 p.m.). The study was approved by the Hokkaido University Animal Committee, and

117 the animals were handled in accordance with the Hokkaido University guidelines for the care and
118 use of laboratory animals.

119 **Glucose tolerance test**

120 OGTTs were performed on rats after 4 and 7 weeks of feeding the test diets in experiment 1. The
121 rats were fasted overnight (16–18 hours), and basal (fasting) blood was collected from the tail vein
122 for the measurement of glucose, insulin, and total GLP-1 levels. After the basal blood collection (0
123 min), a glucose solution was orally administered at a dose of 2 g/kg (4 weeks) or 3 g/kg (7 weeks).
124 Blood samples were collected from the tail vein at 0, 15, 30, 60, 90, and 120 min after the glucose
125 load. The blood samples were collected into tubes containing heparin (final concentration 50
126 IU/mL; Ajinomoto Company, Inc., Tokyo, Japan) and aprotinin [final concentration 500 kallikrein
127 inhibitor units (KIU)/mL; Wako Pure Chemical Industries, Ltd., Osaka, Japan]. Plasma was
128 separated by centrifugation at $2,300 \times g$ for 10 min at 4 °C and frozen at –80 °C until glucose,
129 insulin, and GLP-1 measurements were taken. Plasma glucose, insulin, and total GLP-1
130 concentrations were measured using the Glucose CII Test Kit (Wako), rat insulin enzyme-linked
131 immunosorbent assay (ELISA) kit (AKRIN-010T; Shibayagi Co., Ltd., Gunma, Japan; inter-assay
132 coefficient of variability (CV): < 5%, intra-assay CV: < 5%), and multi-species GLP-1 total ELISA
133 kit (EZGLP1T-36K; Merck Millipore, Darmstadt, Germany; intra-assay CV: < 5%, inter-assay CV:
134 < 12%), respectively.

135 **Portal blood and tissue collection**

136 After 8 weeks (experiment 1) or 8 days (experiment 2) of feeding period, blood samples were
137 collected from the portal vein and abdominal aorta of the rats under sodium pentobarbital anesthesia
138 (50 mg/kg of body weight, somnopentyl injection; Kyoritsu Seiyaku Corporation, Tokyo, Japan)
139 into a syringe containing heparin (final concentration 50 IU/mL), aprotinin (final concentration 500
140 KIU/mL), and DPP-IV inhibitors (final concentration 50 $\mu\text{mol/L}$; DPP4-010; Merck Millipore).

141 Plasma was collected and stored as described above for the measurement of glucose, insulin, GLP-1
142 (total and active), glucose-dependent insulintropic polypeptide (GIP), PYY, and DPP-IV. Active
143 GLP-1 and total GIP levels were measured using the GLP-1 (active) ELISA (EGLP-35K; Merck
144 Millipore; intra-assay CV: $7.4 \pm 1.1\%$, inter-assay CV: $8 \pm 4.8\%$) and Rat/Mouse GIP (total) ELISA
145 (EZRMGIP-55K; Merck Millipore; intra-assay CV: 1.0–5.9%, inter-assay CV: 1.1–5.9%) kits,
146 respectively. Plasma PYY levels were measured using the Mouse/Rat PYY EIA kit (YK081;
147 Yanaihara Institute, Inc., Fujinomiya, Japan; intra-assay CV: 3.1–9.8%, inter-assay CV: 4.2–
148 14.2%). Plasma DPP-IV activity was determined based on the rate of hydrolysis of a surrogate
149 substrate (Gly-Pro-p-nitroaniline, Gly-Pro-pNA, Sigma).

150 After the rats were killed by exsanguination, the jejunum, ileum, cecum, and colon were
151 collected in both of experiments. Luminal contents of the jejunum, ileum, and colon were washed
152 out with cold saline, and then a 2-cm segment and mucosae from another 5-cm segment collected
153 from middle regions of these tissues were collected for GLP-1 content measurement and
154 proglucagon mRNA analysis, respectively. The tissue weight of the cecum as well as the weight
155 and pH of the cecal contents were measured, and the contents were used for short-chain fatty acid
156 (SCFA) measurement. After washing with cold saline, the cecal tissue was divided in half; one half
157 was collected for GLP-1 measurement, and the mucosa from the other half was scraped for
158 proglucagon mRNA analysis. The intestinal segments were immediately frozen in liquid nitrogen
159 and stored at $-80\text{ }^{\circ}\text{C}$. The mucosa samples were immediately transferred to tubes containing buffer
160 RLT (RNeasy Mini Kit; Qiagen, Germany), frozen in liquid nitrogen, and then stored at $-80\text{ }^{\circ}\text{C}$.
161 Mesenteric, retroperitoneal, and epididymal adipose tissue weights were measured, and the sum of
162 those was presented as the visceral adipose tissue weight.

163 **Measurement of glucagon-like peptide-1 content in intestinal tissues**

164 Intestinal segments were homogenized in an ethanol–acid solution (ethanol/water/12 M HCl,

165 74:25:1; 5 mL/g of tissue) [27] and extracted for 24 h at 4 °C. After centrifugation (2,000 × g for 20
166 min), the supernatants were collected and diluted (1,000-fold) with saline to measure total GLP-1
167 levels by ELISA.

168 **Real-time polymerase chain reaction (PCR) analysis**

169 Using a real-time PCR system [28], proglucagon mRNA expression levels were determined.
170 Total RNA was extracted using the RNeasy Mini kit (Qiagen), according to the manufacturer's
171 instructions. Complementary DNA was synthesized using the ReverTra Ace qPCR Master Mix with
172 gDNA Remover (Toyobo Co., Ltd., Osaka, Japan), according to the manufacturer's instructions.
173 Gene expression levels were determined using the Mx3000P Real-Time PCR System (Stratagene,
174 La Jolla, CA, USA) and TaqMan Gene Expression Assay (Life Technologies, Carlsbad, CA, USA)
175 with rat gene-specific predesigned TaqMan primers and probe sets [Rn99999916_s1 for
176 glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Rn00562293_m1 for proglucagon].
177 Relative expression levels were calculated for each sample after normalization to those of GAPDH
178 as a reference gene using the standard curve method.

179 **Measurement of cecal short-chain fatty acids**

180 The cecal contents were collected as described above. The weight of the contents was calculated
181 by subtracting the tissue weight from the total cecal weight. The cecal contents were homogenized
182 with deionized water (300 mg of cecal content in 1.5 ml water). The pH values of the homogenates
183 were measured with a compact pH meter (B-212, Horiba, Ltd., Kyoto, Japan). The organic acids in
184 the cecal homogenates were measured by an ion-exclusion chromatography method using high-
185 performance liquid chromatography (Organic Acid Analysis System, Shimadzu Corporation,
186 Kyoto, Japan) as previously described [29].

187 **Statistical analyses**

188 Data were expressed as means and standard errors (SE) of the mean. Statistical analyses were

189 performed using the JMP Pro version 10.0 software (SAS Institute, Inc., Cary, NC, USA). Statistical
190 significance was assessed using a one-way analysis of variance (ANOVA). Significant differences
191 ($P < 0.05$) between the mean values were determined using the Tukey–Kramer or Dunnett's test, as
192 appropriate (specified in the figure legends). For data of glycemic, insulin, and GLP-1 responses to
193 oral glucose, two-way repeated measurement ANOVA was performed, and the results (effects of time,
194 treatment and the interaction of time and treatment) were presented in the figure legend. Area under
195 the curve (AUC) of plasma glucose, insulin, and GLP-1 levels during the glucose tolerance tests was
196 calculated by the trapezoidal rule. To estimate the degree of insulin resistance during OGTT, AUC
197 of incremental HOMA-IR (iHOMA-IR) was calculated by using incremental AUCs of glucose
198 (mg/dL*2 hr) and insulin (ng/mL*2 hr) as following equation [30]. $\text{HOMA-IR} = \{\text{incremental AUC}$
199 $\text{of glucose (mg/dL*2 hr)} \times \text{incremental AUC of insulin } (\mu\text{U/mL*2 hr})\} / 2,430$, where 1 ng of insulin
200 is equivalent to 26 μ units. Pearson's correlation coefficient (r) and significance of correlations were
201 analyzed as appropriate, and shown in supplementary tables.

202

203

204 **RESULTS**

205 Experiment 1 (feeding for 8 weeks)

206 After 4 weeks, glycemic responses (Fig. 1A) in the three HFS-fed groups appeared to increase
207 compared to that in the control group. The AUC of glucose in the HFS group was significantly
208 higher than that in the control group, but it did not reach significant increment in the RMD- and
209 FOS-supplemented groups. The insulin responses in the three HFS-fed groups were insignificantly
210 higher than those in the control group. The GLP-1 responses in the HFS+RMD and HFS+FOS
211 groups were significantly higher than those in the control group which had no increment of the
212 GLP-1 level but rather decreased after 60 min.

213 Because no GLP-1 elevation was observed in the control group with 2 g/kg of oral glucose (Fig.
214 1C), we increased the dose of glucose to 3 g/kg in OGTT after 7 weeks (Figs. 1E–G). The glucose
215 response at 15 min in the HFS group was significantly larger than that in the control group, but that
216 in the HFS+RMD and HFS+FOS groups were not significantly different from the control group.
217 The insulin response was much higher in the HFS group than in the control group. Although the
218 HFS+RMD and HFS+FOS groups showed increased insulin responses, the increment was smaller
219 than that in the HFS group. The GLP-1 responses in the three HFS-fed groups tended to be higher
220 than those in the control group, but no significant differences were detected. The AUC of
221 incremental HOMA-IR (AUC of iHOMA-IR) was calculated to estimate the degree of insulin
222 resistance during OGTTs (Fig. 1D, H). HFS group had significant increase in AUC of iHOMA-IR
223 compared to control group, but RMD- or FOS-supplemented groups did not, in both of OGTTs.

224 The final body weight, weight gain, and total energy intake in the HFS group were significantly
225 higher than those in the control group after 8 weeks (Table 2), whereas the values for the RMD- and
226 FOS-supplemented groups were slightly lower than the values for the HFS group. The visceral
227 adipose tissue weight (sum of mesenteric, retroperitoneal, epididymal adipose tissue weights) in the
228 HFS group was significantly higher than that in the control group (Table 2), but it did not reach
229 significant increment in the RMD- and FOS-supplemented groups compared to the control group.
230 When compared within the three HFS-fed groups, the visceral adipose tissue weight was
231 significantly lower in the RMD- and FOS-supplemented groups compared to the HFS group
232 (Dunnett's test, $P < 0.05$). Figure 2 shows the change of weekly energy intake over 8 weeks.
233 Although the HFS and HFS+FOS groups had significantly higher energy intake than control group
234 throughout the experimental period (except week 2), energy intake at week 1, 3, and 8 in RMD-
235 supplemented group was not significantly different from control group. When compared within the
236 three HFS-fed groups, the HFS+RMD group had a significantly lower energy intake at weeks 1 and

237 2 compared to the HFS group (Dunnett's test, $P < 0.05$). Decreased energy intake at week 5 and 8 in
238 all the groups is due to overnight fasting for OGTT conducted after 4 and 7 weeks.

239 The portal GLP-1 (active) level was significantly higher in the RMD- and FOS-supplemented
240 groups compared to that in the control group, but it did not significantly elevate in the HFS group
241 (Table 3). The HFS+FOS group had the highest GLP-1 (active and total) and PYY levels, which
242 were significantly different from that observed for the control group. Significant differences were
243 not observed in glucose, insulin, total GIP levels, and DPP-IV activity in the portal plasma.

244 The GLP-1 contents increased in the colon (Fig. 3B) of RMD- and FOS-supplemented groups,
245 but those in the jejunum (data not shown), ileum (data not shown), and cecum (Figs. 3A) did not
246 differ between the treatments. The total content of GLP-1 in the cecum (Fig. 3C) significantly
247 increased in the RMD-fed group compared to that in the HFS group, owing to an increased cecal
248 tissue weight (Table 5). In contrast to the GLP-1 content, the proglucagon mRNA expression levels
249 did not increase in any intestinal region in response to any diet treatment (Table 4). The HFS diet
250 with or without RMD/FOS reduced the proglucagon mRNA expression levels in the ileum.

251 The cecal tissue and contents weights increased in the HFS+RMD and HFS+FOS groups
252 compared to that in the control and HFS groups (Table 5). The cecal pH values (Table 5) were
253 lower in the three HFS-fed groups than in the control group. The HFS group showed relatively low
254 concentrations of each SCFA (Table 5). The acetic and *n*-butyric acid concentrations were higher in
255 the HFS+RMD group than in the HFS group. The propionic acid concentration largely decreased in
256 the HFS group than control group, but it was maintained in the RMD- and FOS-supplemented
257 groups.

258

259 Experiment 2 (feeding for 8 days)

260 The body weight gain during the test period (9 days) was higher in the HFS-fed group than in the
261 control group (Table 6), but the increment was significantly smaller in the HFS+FOS group than in
262 the HFS group. The HFS+RMD group showed an intermediate increment between the HFS and
263 HFS+FOS groups. The visceral adipose tissue weight was significantly higher in the HFS group
264 than in the control group, but the RMD- and FOS-supplemented groups had significantly smaller
265 visceral adipose tissue weight than the HFS group.

266 The daily energy intake (Fig. 4C) was apparently higher in the HFS group than in the control
267 group throughout the feeding period (8 days); however, that in the HFS+RMD and HFS+FOS
268 groups was not significantly higher than in the control group. The total energy intake (Table 6) was
269 significantly lower in the HFS+RMD and HFS+FOS groups than in the HFS group. This reduction
270 was attributed to less energy intake in the dark period (Fig. 4B).

271 The total plasma GLP-1 level showed an increasing trend in the RMD- and FOS-supplemented
272 groups (Table 7), and the value in the RMD+HFS group was significantly different from that in
273 control group when analyzed with Dunnett's test ($P < 0.05$). The plasma PYY level was the highest
274 in the HFS+FOS group. There were no significant differences in the glucose, insulin GIP levels,
275 and DPP-IV activity among the treatments

276 The mucosal GLP-1 content in the colon tended to increase in the HFS+RMD and HFS+FOS
277 groups (Fig. 5B) but was unchanged in the other regions by the treatments (data for jejunum and
278 ileum not shown). Due to the increased tissue weight (Table 9), the GLP-1 content in the whole
279 cecum (Fig. 5C) was significantly higher in the HFS+RMD and HFS+FOS groups than in the
280 control and HFS groups. The proglucagon mRNA expression significantly decreased in the cecum
281 of the HFS+FOS group compared to that of the control group (Table 8).

282 The cecal tissue and contents weights were significantly higher in the HFS+RMD and HFS+FOS
283 groups than in the other two groups (Table 9). The pH values of the cecal contents were

284 significantly lower in the HFS+RMD group than in the control group (Table 9). In the HFS+RMD
285 and HFS+FOS groups, significant increments in the propionic acid concentration were observed,
286 while the other SCFA concentrations did not differ from those in the control group.

287 Within the three HFS-fed groups, total energy intake was significantly ($P < 0.05$) correlated with
288 visceral adipose tissue weight ($r = 0.840$, $P < 0.001$), total GLP-1 in the portal vein ($r = -0.635$, $P =$
289 0.015), total GLP-1 content in the whole cecum ($r = -0.512$, $P = 0.048$), and propionic acid
290 concentration in the cecum ($r = -0.575$, $P = 0.031$).

291

292

293 **Discussion**

294 In contrast to most of studies that investigated GLP-1-promoting effects of various dietary fibers
295 added in the diet at more than 10% (wt/wt) dose [10-12, 15, 20-22], we investigated whether a
296 relatively physiological dose (5% wt/wt) of RMD could promote GLP-1 production in rats fed a
297 high-fat and high-sucrose diet for a long (8 weeks) and a short (8 days) period. After 8 weeks
298 feeding of the HFS+RMD or HFS+FOS diet, the GLP-1 content in the large intestine increased
299 compared to the HFS diet feeding. Though significant fat accumulation was induced by the HFS
300 diet compared to the control diet, RMD- or FOS-supplemented diet did not achieve significant
301 increment of adipose tissue weights. Reductions of energy intake and adipose tissue weight gain,
302 and increment of GLP-1 production were observed within 8 days of feeding the RMD-
303 supplemented diet. These parameters significantly correlated each other, and also correlated with
304 cecal propionate production promoted by RMD or FOS ingestion. The present results suggest that
305 the physiological dose of RMD or FOS can promote endogenous GLP-1 production by the
306 supplementation into an obesogenic diet.

307 In Europe, per capita consumption of sugar is 124 g/day [31], which is equivalent to 496
308 kcal/day. In U.S., per capita consumption of caloric sweeteners (refined sugar, high fructose corn
309 syrup, glucose, dextrose, pure honey, and edible syrups) is estimated 128.9 lb (58.5 kg) /year in
310 2015 (USDA, ERS, Sugar and Sweeteners Outlook, Table 50, <http://www.ers.usda.gov/>), which is
311 equivalent to 160 g = 640 kcal/day. In contrast to US and Europe, Asian and African people
312 consume less than 50 g/day (=200 kcal/day) [31]. As the energy intake in human adults is 2,000-
313 2,500 kcal /day, 500-600 kcal from sugar contributes 20-30% energy of total intake, in average.
314 Although the content of sucrose at 31% energy (40% wt/wt) in the HFS diet is higher than average
315 sugar intake of Europeans and Americans (20-25% energy), the difference between our
316 experimental diet and the sugar consumption in humans would not be extremely large. It was
317 reported that global consumption of saturated fat was 9.4% energy in 2010 [32] with country-
318 specific intake variation from 2.3 to 27.5% energy. The content of lard in the HFS diet at 40%
319 energy (23% wt/wt) is higher than the human situation above, however, it has been recognized that
320 a high consumption of saturated fats is linked to metabolic syndrome, and high fat diet containing
321 lard is generally used in animal study as obesogenic diets [33]. Although the present study has a
322 limitation that the HFS diet may not perfectly mimic human diet, humans having higher amount of
323 sugar and saturated fats would easily get obese. It has not been defined the 'ideal' obesogenic diet
324 nor established a rodent model that accurately mimic the human obesity and accompanied
325 symptoms [33]. Based on these backgrounds and to accelerate the induction of overweight, we used
326 the HFS diet in the present study.

327 The glycemic response significantly increased in the rats fed the HFS diet for 4 weeks but not in
328 rats fed the HFS diet supplemented with RMD or FOS (Fig. 1A). The insulin responses were almost
329 similar in the three HFS-fed groups (Fig. 1B), suggesting that the insulin sensitivity was not
330 significantly impaired in the HFS+RMD and HFS+FOS groups (Fig. 1D). Interestingly, the GLP-1

331 secretory response increased in the HFS+RMD and HFS+FOS groups (Fig. 1C). Because the basal
332 (0 min) GLP-1 levels did not differ among the treatments, the result suggests that the sensitivity of
333 L cells in the small intestine to luminal glucose was enhanced by the chronic feeding of the RMD-
334 or FOS-supplemented diets. Although the cecal and colonic GLP-1 contents increased in these
335 groups, GLP-1 in the large intestine would not participate in the postprandial rapid GLP-1 response.
336 This also supports the notion that L-cell sensitivity to glucose was enhanced by the continuous
337 RMD or FOS intake.

338 We recently demonstrated that 8 weeks feeding of the HFS diet enhanced postprandial GLP-1
339 secretion based on a meal tolerance test [34]. This effect was observed after 7 weeks of HFS
340 feeding but not after 4 weeks. In the present study, the GLP-1 response to oral glucose was already
341 enhanced by feeding the HFS diet for 4 weeks. It appears that the sensitivity of L cells to glucose is
342 readily adaptive compared to the sensitivity to a “meal”.

343 It is still controversial whether GLP-1 secretion is impaired under obesity, glucose intolerance,
344 and diabetic conditions [35-37]. We speculate that the enhanced GLP-1 response to a meal [34], as
345 well as to oral glucose as observed in the present study and in a previous human study [38], has a
346 protective role against the development of postprandial hyperglycemia induced by continuous
347 feeding of high-energy diets. The enhanced GLP-1 secretion caused by repeated feeding of the HFS
348 and RMD/FOS-supplemented diets might be induced through distinct mechanisms. Further studies
349 are needed to understand the physiological relevance and underlying mechanisms of the RMD- and
350 FOS-enhanced L-cell sensitivity.

351 After 7 weeks (Figs. 1E-H), the glycemic response at 15 min was the highest in the HFS group,
352 while the RMD- and FOS-supplemented groups showed slightly smaller responses than the HFS
353 group, which were accompanied by smaller insulin responses. This still suggests that the
354 postprandial insulin sensitivity was not significantly impaired in the RMD- and FOS-supplemented

355 groups after 7 weeks (Fig. 1H). Although the GLP-1 response to oral glucose in RMD- and FOS-
356 supplemented groups did not differ from the HFS group, increased fasting GLP-1 levels (Table 3)
357 might contribute to the attenuation of insulin resistance since improving insulin sensitivity is one of
358 the multiple effects of GLP-1 receptor activation [2, 39, 40].

359 The body and adipose tissue weights were expectedly increased by feeding the HFS diet
360 compared to feeding the control diet, even after 8 days of feeding (Table 2 and 6). However, the
361 RMD or FOS supplementation did not result in significant increments in the adipose tissue weight.
362 The suppressive effect of RMD on the HFS diet-induced excessive energy intake in the early period
363 (Fig. 2) was reproduced in experiment 2 by monitoring daytime (light period) and nighttime (dark
364 period) food intake everyday (Fig. 4). This was clearly observed during nighttime, the usual eating
365 time for rodents. The reduced fat accumulation (Table 2 and 6) could be attributed to these effects.
366 In addition, there are several possible mechanisms for reducing fat accumulation by prebiotic fibers.
367 RMD is reported to reduce lipid absorption [41], and FOS or oligofructose modulates lipid
368 metabolism [42, 43].

369 Oligofructose [44-49] and RMD [19] have been reported for their satiety effects on subjective
370 appetite accompanied by increased GLP-1 and/or PYY levels in animals or healthy humans,
371 suggesting a possibility of these prebiotics to contribute to control energy intake and body weight
372 for a long-term. Although elevated portal GLP-1 levels in RMD- and FOS-supplemented groups
373 were not significantly different from that in the HFS group in experiment 2, portal GLP-1 level (but
374 not PYY level) and cecal GLP-1 content were inversely correlated with total energy intake. Thus,
375 the increased plasma GLP-1 level after 8 days of feeding the RMD- and FOS-supplemented diet is
376 likely responsible for the reduced energy intake in the present study.

377 One of the major effects of prebiotic fibers is modulation of gut fermentation. A number of
378 studies have demonstrated effects of the fibers on gut microbiota in animals and humans. SCFAs

379 are potent stimuli for GLP-1 and PYY secretion [50]. The plasma (active or total) GLP-1 levels
380 tended to be increased by the HFS diet compared to the control diet in experiment 1, but the
381 increment became statistically significant in the RMD- and FOS-supplemented groups (Table 3).
382 The increased production of SCFAs such as acetate, propionate, and *n*-butyrate could be responsible
383 for the significant elevation of production and secretion of GLP-1. Recent reports [51, 52]
384 demonstrated that GLP-1/PYY secretion was potently stimulated by luminal propionate in vivo
385 (rats and mice, and humans), and by exposure to propionate in human and mice colonic culture
386 models in vitro, suggesting roles for propionate in inducing GLP-1/PYY secretion and reducing
387 appetite. Therefore, the increased levels of propionate induced by RMD or FOS in both experiments
388 are likely involved in reduced energy intake through increased GLP-1 and PYY secretion. Other
389 SCFA functions [53], besides increasing these gut hormones, could also contribute to reducing
390 energy intake and fat mass.

391 In comparison among HFS-fed 3 groups, RMD and FOS supplementations increased propionate
392 production in the cecum (both per g content and per total content) in both of experiments. The HFS
393 diet reduced propionate production after 8-weeks feeding, but the effect did not appear after 8-days
394 feeding. These results indicate that the HFS diet has suppressive effect on propionate production
395 after a relatively long feeding period (~8 weeks), but prebiotics such as RMD and FOS exert
396 promoting effect on propionate production immediately (~8 days) after the intervention.

397 By correlation analysis (Supplemental Table 1 and 2) among HFS-fed 3 groups, significant
398 correlations were observed between following combinations, in experiment 2 (8 day-feeding):
399 [cecal propionate ($\mu\text{mol/g}$ content) and cecal GLP-1 (pmol/tissue); $r = 0.6166$, $P = 0.0188$], [cecal
400 GLP-1 (pmol/tissue) and portal total GLP-1 (pM); $r = 0.5845$, $P = 0.0282$], [portal total GLP-1
401 (pM) and total energy intake (kcal); $r = -0.6353$, $P = 0.0146$]. However, portal PYY did not
402 significantly correlated with various parameters tested. These results suggests that propionate

403 production increased by RMD/FOS promoted GLP-1 production in the large intestine, which
404 contributed to elevated fasting plasma GLP-1 level and resulted in energy intake.

405 In experiment 1 (8 weeks feeding), while a significant correlation was observed between cecal
406 propionate (pmol/tissue) and cecal GLP-1 (pmol/g tissue) ($r = 0.6415$, $P = 0.0013$), cecal GLP-1 did
407 not significantly correlated with plasma GLP-1. Furthermore, plasma GLP-1 and PYY did not
408 inversely correlate with energy intake. Possibly, above pathway raised from experiment 2 might
409 have been impaired by a long time feeding with HFS. Although we did not examined in the present
410 study, postprandial GLP-1 secretions might be enhanced in RMD/FOS-treated groups due to
411 increased GLP-1 pool in the large intestine.

412 GLP-1 is produced in enteroendocrine L cells scattered throughout the intestinal epithelium, with
413 a larger population in the ileum and large intestine than in the proximal small intestine [54]. This
414 has been confirmed by measuring the GLP-1 content in separated intestinal segments from the
415 control rats in the present study (Figs. 3 and 5). The GLP-1 concentration (pmol/g of tissue)
416 significantly changed only in the colon after 8 weeks of feeding the RMD- or FOS-containing diet,
417 but the increment was not significant in the short-term experiment (8 days). This indicates that
418 colonic tissue is more sensitive to the continuous feeding of prebiotic fibers than the other intestinal
419 regions, including the cecum. It is quite interesting how such a difference could appear between the
420 cecum and colon. Possibly, the compositions of luminal SCFAs and microbiota differ between these
421 regions. Present results reveled that the changes in the mRNA expression levels at the time
422 (overnight fasted) do not directly explain the differences in the GLP-1 content between the
423 treatments since the mRNA expression levels was not proportional to GLP-1 contents in each
424 region in both experiments. There might be other factors affecting GLP-1 contents in the tissue, for
425 example, DPP-IV activity that degrades GLP-1, and prohormone convertase 1/3 activity, which is

426 involved in posttranslational processing of the proglucagon peptide to produce the GLP-1 peptide
427 [55, 56].

428 We evaluated the effects of RMD and FOS added at 5% (wt/wt) to the HFS diet in the present
429 and previous studies [9]. The dose of 5% (wt/wt) in an animal study is considered equivalent to 20–
430 30 g/day in the case of humans [23, 24], and the recommended dose of dietary fiber is 20–38 g/day
431 (14 g/1000 kcal) in human adults [25]. Therefore, the 5% supplementation in an experimental diet
432 in the present study is thought to be more suitable than the 10% dose that has been used in the
433 majority of animal studies on prebiotic fibers, and the present results could have translational
434 potential for human applications.

435 In summary, rats were fed a high-fat and high-sucrose diet with or without 5% RMD/FOS for 8
436 weeks. Feeding the HFS diet resulted in increased glycemic response to oral glucose, but
437 supplementation of RMD or FOS did not achieve significant increments in glycemia and an index
438 of insulin resistance, with increased GLP-1 secretion. Feeding RMD or FOS-supplemented diet
439 increased GLP-1 content in the large intestine. Energy intake and adipose tissue weight gain were
440 reduced by feeding the RMD or FOS-supplemented diet for 8 days, and these parameters inversely
441 correlated with cecal propionate, plasma and tissue GLP-1 levels. These results demonstrate that a
442 physiological dose of prebiotic fiber rapidly promotes GLP-1 production in rats fed an obesogenic
443 high-fat and high-sucrose diet, which would effectively help to prevent excess energy intake and fat
444 accumulation.

445

446 **Financial support:** The research was supported by JSPS KAKENHI Grant Number 26252016.

447

448 **Conflict of Interest:** Y. Kishimoto and S. Kanahori are employees of Matsutani Chemical Industry.
449 T. Hira, R. Suto, and H. Hara, no conflicts of interest.

450

451 **Author's contributions to the manuscript**

452 T. H., R. S., Y. K. and H. H. designed research; T. H. and R. S. conducted research and analyzed
453 data; T. H., R. S., Y. K., S. K. and H. H. wrote the paper. T. H. had primary responsibility for final
454 content. All authors read and approved the final manuscript.

455

456 **References**

- 457 1. Cho YM, Fujita Y, Kieffer TJ (2014) Glucagon-like peptide-1: glucose homeostasis and
458 beyond. *Annu Rev Physiol* 76:535-559. doi:10.1146/annurev-physiol-021113-170315
- 459 2. Kim YO, Schuppan D (2012) When GLP-1 hits the liver: a novel approach for insulin
460 resistance and NASH. *Am J Physiol Gastrointest Liver Physiol* 302 (8):G759-761.
461 doi:10.1152/ajpgi.00078.2012
- 462 3. Nauck M (2016) Incretin therapies: highlighting common features and differences in the
463 modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4
464 inhibitors. *Diabetes Obes Metab* 18 (3):203-216. doi:10.1111/dom.12591
- 465 4. Diakogiannaki E, Gribble FM, Reimann F (2012) Nutrient detection by incretin hormone
466 secreting cells. *Physiol Behav* 106 (3):387-393. doi:10.1016/j.physbeh.2011.12.001
- 467 5. Higuchi N, Hira T, Yamada N, Hara H (2013) Oral Administration of Corn Zein Hydrolysate
468 Stimulates GLP-1 and GIP Secretion and Improves Glucose Tolerance in Male Normal Rats
469 and Goto-Kakizaki Rats. *Endocrinology* 154 (9):3089-3098. doi:10.1210/en.2012-2275
- 470 6. Ishikawa Y, Hira T, Inoue D, Harada Y, Hashimoto H, Fujii M, Kadowaki M, Hara H (2015)
471 Rice protein hydrolysates stimulate GLP-1 secretion, reduce GLP-1 degradation, and lower the
472 glycemic response in rats. *Food Funct* 6 (8):2525-2534. doi:10.1039/c4fo01054j
- 473 7. Greenfield JR, Farooqi IS, Keogh JM, Henning E, Habib AM, Blackwood A, Reimann F,

- 474 Holst JJ, Gribble FM (2009) Oral glutamine increases circulating glucagon-like peptide 1,
475 glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. *Am J Clin*
476 *Nutr* 89 (1):106-113. doi:10.3945/ajcn.2008.26362
- 477 8. Jakubowicz D, Froy O, Ahrén B, Boaz M, Landau Z, Bar-Dayana Y, Ganz T, Barnea M,
478 Wainstein J (2014) Incretin, insulinotropic and glucose-lowering effects of whey protein pre-
479 load in type 2 diabetes: a randomised clinical trial. *Diabetologia* 57 (9):1807-1811.
480 doi:10.1007/s00125-014-3305-x
- 481 9. Hira T, Ikee A, Kishimoto Y, Kanahori S, Hara H (2015) Resistant maltodextrin promotes
482 fasting glucagon-like peptide-1 secretion and production together with glucose tolerance in
483 rats. *Br J Nutr* 114 (1):34-42. doi:10.1017/S0007114514004322
- 484 10. Cani PD, Dewever C, Delzenne NM (2004) Inulin-type fructans modulate gastrointestinal
485 peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. *Br J Nutr*
486 92 (3):521-526
- 487 11. Cani PD, Daubioul CA, Reusens B, Remacle C, Catillon G, Delzenne NM (2005) Involvement
488 of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering effect of
489 oligofructose in streptozotocin-treated rats. *J Endocrinol* 185 (3):457-465.
490 doi:10.1677/joe.1.06100
- 491 12. Delzenne NM, Cani PD, Daubioul C, Neyrinck AM (2005) Impact of inulin and oligofructose
492 on gastrointestinal peptides. *Br J Nutr* 93 Suppl 1:S157-161
- 493 13. Fastinger ND, Karr-Lilienthal LK, Spears JK, Swanson KS, Zinn KE, Nava GM, Ohkuma K,
494 Kanahori S, Gordon DT, Fahey GC (2008) A novel resistant maltodextrin alters
495 gastrointestinal tolerance factors, fecal characteristics, and fecal microbiota in healthy adult
496 humans. *J Am Coll Nutr* 27 (2):356-366
- 497 14. Reimer RA, Russell JC (2008) Glucose tolerance, lipids, and GLP-1 secretion in JCR:LA-cp

- 498 rats fed a high protein fiber diet. *Obesity (Silver Spring)* 16 (1):40-46.
499 doi:10.1038/oby.2007.16
- 500 15. Zhou J, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, Shen L, Danna SC, Tripathy S,
501 Hegsted M, Keenan MJ (2008) Dietary resistant starch upregulates total GLP-1 and PYY in a
502 sustained day-long manner through fermentation in rodents. *Am J Physiol Endocrinol Metab*
503 295 (5):E1160-1166. doi:10.1152/ajpendo.90637.2008
- 504 16. Hashizume C, Kishimoto Y, Kanahori S, Yamamoto T, Okuma K, Yamamoto K (2012)
505 Improvement effect of resistant maltodextrin in humans with metabolic syndrome by
506 continuous administration. *J Nutr Sci Vitaminol (Tokyo)* 58 (6):423-430
- 507 17. Livesey G, Tagami H (2009) Interventions to lower the glycemic response to carbohydrate
508 foods with a low-viscosity fiber (resistant maltodextrin): meta-analysis of randomized
509 controlled trials. *Am J Clin Nutr* 89 (1):114-125. doi:10.3945/ajcn.2008.26842
- 510 18. Chu HF, Pan MH, Ho CT, Tseng YH, Wang WW, Chau CF (2014) Variations in the efficacy
511 of resistant maltodextrin on body fat reduction in rats fed different high-fat models. *J Agric*
512 *Food Chem* 62 (1):192-197. doi:10.1021/jf404809v
- 513 19. Ye Z, Arumugam V, Haugabrooks E, Williamson P, Hendrich S (2015) Soluble dietary fiber
514 (Fibersol-2) decreased hunger and increased satiety hormones in humans when ingested with a
515 meal. *Nutr Res* 35 (5):393-400. doi:10.1016/j.nutres.2015.03.004
- 516 20. Adam CL, Gratz SW, Peinado DI, Thomson LM, Garden KE, Williams PA, Richardson AJ,
517 Ross AW (2016) Effects of Dietary Fibre (Pectin) and/or Increased Protein (Casein or Pea) on
518 Satiety, Body Weight, Adiposity and Caecal Fermentation in High Fat Diet-Induced Obese
519 Rats. *PLoS One* 11 (5):e0155871. doi:10.1371/journal.pone.0155871
- 520 21. den Besten G, Gerding A, van Dijk TH, Ciapaite J, Bleeker A, van Eunen K, Havinga R,
521 Groen AK, Reijngoud DJ, Bakker BM (2015) Protection against the Metabolic Syndrome by

- 522 Guar Gum-Derived Short-Chain Fatty Acids Depends on Peroxisome Proliferator-Activated
523 Receptor γ and Glucagon-Like Peptide-1. *PLoS One* 10 (8):e0136364.
524 doi:10.1371/journal.pone.0136364
- 525 22. Adam CL, Williams PA, Dalby MJ, Garden K, Thomson LM, Richardson AJ, Gratz SW, Ross
526 AW (2014) Different types of soluble fermentable dietary fibre decrease food intake, body
527 weight gain and adiposity in young adult male rats. *Nutr Metab (Lond)* 11:36.
528 doi:10.1186/1743-7075-11-36
- 529 23. Parnell JA, Reimer RA (2012) Prebiotic fiber modulation of the gut microbiota improves risk
530 factors for obesity and the metabolic syndrome. *Gut Microbes* 3 (1):29-34.
531 doi:10.4161/gmic.19246
- 532 24. Cluny NL, Eller LK, Keenan CM, Reimer RA, Sharkey KA (2015) Interactive effects of
533 oligofructose and obesity predisposition on gut hormones and microbiota in diet-induced obese
534 rats. *Obesity (Silver Spring)* 23 (4):769-778. doi:10.1002/oby.21017
- 535 25. Turner ND, Lupton JR (2011) Dietary fiber. *Adv Nutr* 2 (2):151-152.
536 doi:10.3945/an.110.000281
- 537 26. Reeves PG (1997) Components of the AIN-93 diets as improvements in the AIN-76A diet. *J*
538 *Nutr* 127 (5 Suppl):838S-841S
- 539 27. Cani PD, Hoste S, Guiot Y, Delzenne NM (2007) Dietary non-digestible carbohydrates
540 promote L-cell differentiation in the proximal colon of rats. *Br J Nutr* 98 (1):32-37.
541 doi:10.1017/S0007114507691648
- 542 28. Iwaya H, Lee JS, Yamagishi S, Shinoki A, Lang W, Thawornkuno C, Kang HK, Kumagai Y,
543 Suzuki S, Kitamura S, Hara H, Okuyama M, Mori H, Kimura A, Ishizuka S (2012) The delay
544 in the development of experimental colitis from isomaltosyloligosaccharides in rats is
545 dependent on the degree of polymerization. *PLoS One* 7 (11):e50658.

- 546 doi:10.1371/journal.pone.0050658
- 547 29. Miyazato S, Nakagawa C, Kishimoto Y, Tagami H, Hara H (2010) Promotive effects of
548 resistant maltodextrin on apparent absorption of calcium, magnesium, iron and zinc in rats. *Eur*
549 *J Nutr* 49 (3):165-171. doi:10.1007/s00394-009-0062-6
- 550 30. J. Cacho, J. Sevillano, J. de Castro, E. Herrera and M. P. Ramos (2008) Validation of simple
551 indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats. *Am*
552 *J Physiol Endocrinol Metab* 295:E1269-E1276. doi: 10.1152/ajpendo.90207.2008
- 553 31. Tappy L, Lê KA (2010) Metabolic effects of fructose and the worldwide increase in obesity.
554 *Physiol Rev* 90 (1):23-46. doi:10.1152/physrev.00019.2009
- 555 32. Micha R, Khatibzadeh S, Shi P, Fahimi S, Lim S, Andrews KG, Engell RE, Powles J, Ezzati
556 M, Mozaffarian D, NutriCoDE GBoDNaCDEG (2014) Global, regional, and national
557 consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including
558 266 country-specific nutrition surveys. *BMJ* 348:g2272. doi: 10.1136/bmj.g2272
- 559 33. Lai M, Chandrasekera PC, Barnard ND (2014) You are what you eat, or are you? The
560 challenges of translating high-fat-fed rodents to human obesity and diabetes. *Nutr Diabetes*
561 4:e135. doi:10.1038/nutd.2014.30
- 562 34. Nakajima S, Hira T, Hara H (2015) Postprandial glucagon-like peptide-1 secretion is increased
563 during the progression of glucose intolerance and obesity in high-fat/high-sucrose diet-fed rats.
564 *Br J Nutr* 113 (9):1477-1488. doi:10.1017/S0007114515000550
- 565 35. Theodorakis MJ (2015) Comment on Færch et al. GLP-1 Response to Oral Glucose Is
566 Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex:
567 The ADDITION-PRO Study. *Diabetes* 2015;64:2513-2525. *Diabetes* 64 (9):e28-29; discussion
568 e30-21. doi:10.2337/db15-0614
- 569 36. Færch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, Pedersen O, Hansen T,

- 570 Lauritzen T, Sandbæk A, Holst JJ, Jørgensen ME (2015) GLP-1 Response to Oral Glucose Is
571 Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex:
572 The ADDITION-PRO Study. *Diabetes* 64 (7):2513-2525. doi:10.2337/db14-1751
- 573 37. Smushkin G, Sathananthan A, Man CD, Zinsmeister AR, Camilleri M, Cobelli C, Rizza RA,
574 Vella A (2012) Defects in GLP-1 response to an oral challenge do not play a significant role in
575 the pathogenesis of prediabetes. *J Clin Endocrinol Metab* 97 (2):589-598. doi:10.1210/jc.2011-
576 2561
- 577 38. Numao S, Kawano H, Endo N, Yamada Y, Konishi M, Takahashi M, Sakamoto S (2012)
578 Short-term low carbohydrate/high-fat diet intake increases postprandial plasma glucose and
579 glucagon-like peptide-1 levels during an oral glucose tolerance test in healthy men. *Eur J Clin*
580 *Nutr* 66 (8):926-931. doi:10.1038/ejcn.2012.58
- 581 39. Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS,
582 Erickson MR, Napora J, Parkes DG, Roth JD (2012) Glucagon-like peptide-1 receptor
583 agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic
584 steatohepatitis in mice. *Am J Physiol Gastrointest Liver Physiol* 302 (8):G762-772.
585 doi:10.1152/ajpgi.00476.2011
- 586 40. Wu H, Sui C, Xu H, Xia F, Zhai H, Zhang H, Weng P, Han B, Du S, Lu Y (2014) The GLP-1
587 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer
588 studies in the basal state and during hyperinsulinemic-euglycemic clamp. *J Diabetes Res*
589 2014:524517. doi:10.1155/2014/524517
- 590 41. Kishimoto Y, Oga H, Tagami H, Okuma K, Gordon DT (2007) Suppressive effect of resistant
591 maltodextrin on postprandial blood triacylglycerol elevation. *Eur J Nutr* 46 (3):133-138.
592 doi:10.1007/s00394-007-0643-1
- 593 42. Beylot M (2005) Effects of inulin-type fructans on lipid metabolism in man and in animal

- 594 models. *Br J Nutr* 93 Suppl 1:S163-168
- 595 43. Phuwamongkolwiwat P, Suzuki T, Hira T, Hara H (2014) Fructooligosaccharide augments
596 benefits of quercetin-3-O- β -glucoside on insulin sensitivity and plasma total cholesterol with
597 promotion of flavonoid absorption in sucrose-fed rats. *Eur J Nutr* 53 (2):457-468.
598 doi:10.1007/s00394-013-0546-2
- 599 44. Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, Burcelin R (2006) Improvement
600 of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional
601 glucagon-like peptide 1 receptor. *Diabetes* 55 (5):1484-1490
- 602 45. Cani PD, Neyrinck AM, Maton N, Delzenne NM (2005) Oligofructose promotes satiety in rats
603 fed a high-fat diet: involvement of glucagon-like Peptide-1. *Obes Res* 13 (6):1000-1007.
604 doi:10.1038/oby.2005.117
- 605 46. Verhoef SP, Meyer D, Westerterp KR (2011) Effects of oligofructose on appetite profile,
606 glucagon-like peptide 1 and peptide YY3-36 concentrations and energy intake. *Br J Nutr* 106
607 (11):1757-1762. doi:10.1017/S0007114511002194
- 608 47. Liber A, Szajewska H (2013) Effects of inulin-type fructans on appetite, energy intake, and
609 body weight in children and adults: systematic review of randomized controlled trials. *Ann*
610 *Nutr Metab* 63 (1-2):42-54. doi:10.1159/000350312
- 611 48. Pedersen C, Lefevre S, Peters V, Patterson M, Ghatei MA, Morgan LM, Frost GS (2013) Gut
612 hormone release and appetite regulation in healthy non-obese participants following
613 oligofructose intake. A dose-escalation study. *Appetite* 66:44-53.
614 doi:10.1016/j.appet.2013.02.017
- 615 49. Daud NM, Ismail NA, Thomas EL, Fitzpatrick JA, Bell JD, Swann JR, Costabile A, Childs
616 CE, Pedersen C, Goldstone AP, Frost GS (2014) The impact of oligofructose on stimulation of
617 gut hormones, appetite regulation and adiposity. *Obesity (Silver Spring)* 22 (6):1430-1438.

618 doi:10.1002/oby.20754

619 50. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse
620 J, Reimann F, Gribble FM (2012) Short-chain fatty acids stimulate glucagon-like peptide-1
621 secretion via the G-protein-coupled receptor FFAR2. *Diabetes* 61 (2):364-371.

622 doi:10.2337/db11-1019

623 51. Psichas A, Sleeth ML, Murphy KG, Brooks L, Bewick GA, Hanyaloglu AC, Ghatei MA,
624 Bloom SR, Frost G (2015) The short chain fatty acid propionate stimulates GLP-1 and PYY
625 secretion via free fatty acid receptor 2 in rodents. *Int J Obes (Lond)* 39 (3):424-429.

626 doi:10.1038/ijo.2014.153

627 52. Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SE,
628 MacDougall K, Preston T, Tedford C, Finlayson GS, Blundell JE, Bell JD, Thomas EL, Mt-Isa
629 S, Ashby D, Gibson GR, Kolida S, Dhillon WS, Bloom SR, Morley W, Clegg S, Frost G (2015)
630 Effects of targeted delivery of propionate to the human colon on appetite regulation, body
631 weight maintenance and adiposity in overweight adults. *Gut* 64 (11):1744-1754.

632 doi:10.1136/gutjnl-2014-307913

633 53. Byrne CS, Chambers ES, Morrison DJ, Frost G (2015) The role of short chain fatty acids in
634 appetite regulation and energy homeostasis. *Int J Obes (Lond)* 39 (9):1331-1338.

635 doi:10.1038/ijo.2015.84

636 54. Svendsen B, Pedersen J, Albrechtsen NJ, Hartmann B, Toräng S, Rehfeld JF, Poulsen SS,
637 Holst JJ (2015) An analysis of cosecretion and coexpression of gut hormones from male rat
638 proximal and distal small intestine. *Endocrinology* 156 (3):847-857. doi:10.1210/en.2014-1710

639 55. Rouillé Y, Kantengwa S, Irminger JC, Halban PA (1997) Role of the prohormone convertase
640 PC3 in the processing of proglucagon to glucagon-like peptide 1. *J Biol Chem* 272 (52):32810-
641 32816

642 56. Morimoto K, Watanabe M, Sugizaki T, Irie J, Itoh H (2016) Intestinal Bile Acid Composition
643 Modulates Prohormone Convertase 1/3 (PC1/3) Expression and Consequent GLP-1 Production
644 in Male Mice. *Endocrinology* 157 (3):1071-1081. doi:10.1210/en.2015-1551
645

646 **Tables**647 **Table 1. Test diet composition**

| Ingredient | Control | HFS | HFS+RMD | HFS+FOS |
|--------------------------------------|--------------|---------|---------|---------|
| | g/kg of diet | | | |
| Cornstarch | 397.486 | – | – | – |
| Casein ¹⁾ | 200 | 200 | 200 | 200 |
| Dextrinized cornstarch ²⁾ | 132 | – | – | – |
| Sucrose | 100 | 399.486 | 399.486 | 399.486 |
| Soybean oil | 70 | 70 | 70 | 70 |
| Lard oil | – | 230 | 230 | 230 |
| Fiber | | | | |
| Cellulose ³⁾ | 50 | 50 | – | – |
| RMD ⁴⁾ | – | – | 50 | – |
| FOS ⁵⁾ | – | – | – | 50 |
| Mineral mixture ⁶⁾ | 35 | 35 | 35 | 35 |
| Vitamin mixture ⁶⁾ | 10 | 10 | 10 | 10 |
| L-Cystine | 3 | 3 | 3 | 3 |
| Choline bitartrate | 2.5 | 2.5 | 2.5 | 2.5 |
| <i>tert</i> -Butylhydroquinone | 0.014 | 0.014 | 0.014 | 0.014 |
| Energy density (kcal/g) | 3.96 | 5.11 | 5.16 | 5.21 |

648 1) Acid Casein (Fonterra, Ltd., Auckland, New Zealand);

649 2) TK-16 (Matsutani Chemical Industry Co., Ltd., Hyogo, Japan);

650 3) Avicel PH102 (Asahi Kasei Chemicals Corporation, Tokyo, Japan);

651 4) Resistant maltodextrin (Fibersol 2, Matsutani Chemical Industry, Hyogo, Japan);

652 5) Fructooligosaccharides (Meiologo-P, Meiji Co., Ltd., Tokyo, Japan);

653 6) Mineral and vitamin mixtures were prepared according to the AIN-93G formulation.

654

655 **Table 2. Body weight, visceral adipose tissue weight, and energy intake of rats fed**
 656 **test diets for 8 weeks.**

| | Control | | HFS | | HFS+RMD | | HFS+FOS | | ANOVA |
|-------------------------------|---------|-------------------|---------|-------------------|---------|--------------------|---------|--------------------|---------|
| | Mean | SE | Mean | SE | Mean | SE | Mean | SE | P value |
| Initial body Weight (g) | 209 ± | 3 | 205 ± | 4 | 207 ± | 3 | 206 ± | 3 | 0.882 |
| Final body Weight (g) | 515 ± | 12 ^b | 607 ± | 11 ^a | 579 ± | 17 ^a | 596 ± | 14 ^a | 0.001 |
| Body weight gain (g) | 306 ± | 10 ^b | 401 ± | 13 ^a | 372 ± | 16 ^a | 390 ± | 13 ^a | <0.001 |
| Visceral adipose (g/100 g BW) | 8.18 ± | 0.49 ^b | 11.92 ± | 0.61 ^a | 10.07 ± | 0.54 ^{ab} | 10.10 ± | 0.42 ^{ab} | 0.001 |
| Total Energy intake (kcal) | 5440 ± | 154 ^b | 6280 ± | 148 ^a | 6142 ± | 179 ^a | 6275 ± | 176 ^a | 0.004 |

657 The values are the means ± SE ($n = 7-8$). The values that do not share the same letter
 658 differ significantly between the treatments ($P < 0.05$, Tukey–Kramer test).

659
 660
 661

662 **Table 3. Glucose, insulin, GLP-1, GIP, PYY levels and DPP-IV activity in portal**
 663 **plasma of rats fed test diets for 8 weeks.**

| | Control | | HFS | | HFS+RMD | | HFS+FOS | | ANOVA |
|-------------------|---------|-------------------|---------|--------------------|---------|--------------------|---------|-------------------|---------|
| | Mean | SE | Mean | SE | Mean | SE | Mean | SE | P value |
| Glucose (mg/dl) | 102.6 ± | 2.3 ^{NS} | 120.8 ± | 6.3 | 105.6 ± | 4.6 | 118.4 ± | 4.3 | 0.023 |
| Insulin (nM) | 13.8 ± | 1.6 ^{NS} | 12.8 ± | 2.9 | 10.3 ± | 1.5 | 9.4 ± | 2.7 | 0.493 |
| Total GLP-1 (pM) | 45.1 ± | 3.8 ^b | 60.4 ± | 3.2 ^{ab} | 59.4 ± | 7.2 ^{ab} | 67.8 ± | 5.6 ^a | 0.050 |
| Active GLP-1 (pM) | 11.2 ± | 1.3 ^b | 32.2 ± | 3.4 ^{ab} | 38.7 ± | 7.3 ^a | 49.9 ± | 10.4 ^a | 0.007 |
| Total GIP (pM) | 12.1 ± | 1.6 ^{NS} | 13.4 ± | 0.7 | 12.7 ± | 0.7 | 9.5 ± | 1.3 | 0.133 |
| PYY (ng/mL) | 1.15 ± | 0.12 ^b | 1.37 ± | 0.07 ^{ab} | 1.66 ± | 0.13 ^{ab} | 1.86 ± | 0.22 ^a | 0.010 |
| DPP-IV (mU/mL) | 15.8 ± | 1.9 ^{NS} | 18.1 ± | 1.1 | 17.2 ± | 2.2 | 18.6 ± | 1.9 | 0.732 |

664 The values are the means ± SE ($n = 7-8$). The values that do not share the same letter
 665 differ significantly between the treatments ($P < 0.05$, Tukey–Kramer test).

666
 667

668 **Table 4. Proglucagon mRNA expression in intestinal tissues of rats fed test diets for**
 669 **8 weeks.**

| Proglucagon/GAPDH (relative to Control) | Control | | HFS | | HFS+RMD | | HFS+FOS | | ANOVA |
|--|--------------------------|----|---------------------------|----|--------------------------|----|---------------------------|----|---------|
| | Mean | SE | Mean | SE | Mean | SE | Mean | SE | P value |
| Jejunum | 1.00 ± 0.23 | | 1.16 ± 0.20 | | 1.02 ± 0.09 | | 1.16 ± 0.17 | | 0.526 |
| Ileum | 1.00 ± 0.18 ^a | | 0.51 ± 0.10 ^{ab} | | 0.47 ± 0.09 ^b | | 0.55 ± 0.13 ^{ab} | | 0.022 |
| Cecum | 1.00 ± 0.27 | | 1.55 ± 0.27 | | 1.46 ± 0.19 | | 0.97 ± 0.15 | | 0.165 |
| Colon | 1.00 ± 0.25 | | 0.85 ± 0.15 | | 0.91 ± 0.11 | | 1.12 ± 0.31 | | 0.097 |

670 Total RNA was used for real-time PCR analysis. Proglucagon mRNA expression levels
 671 were normalized to that of GAPDH, and the data are expressed as relative changes
 672 compared to the control group. The values are the means ± SE ($n = 7-8$). The values are
 673 the means ± SE ($n = 7-8$). The values that do not share the same letter differ significantly
 674 between the treatments ($P < 0.05$, Tukey–Kramer test).

675

676

677

678 **Table 5. Cecal tissue, content weights, pH and short chain fatty acid concentrations**
 679 **of rats fed test diets for 8 weeks.**

| | Control | | HFS | | HFS+RMD | | HFS+FOS | | ANOVA |
|-----------------------------------|---------------------------|----|---------------------------|----|---------------------------|----|---------------------------|----|---------|
| | Mean | SE | Mean | SE | Mean | SE | Mean | SE | P value |
| Cecal tissue (g/100 g BW) | 0.24 ± 0.02 ^b | | 0.18 ± 0.01 ^b | | 0.35 ± 0.02 ^a | | 0.36 ± 0.04 ^a | | <0.001 |
| Cecal content (g/100 g BW) | 0.34 ± 0.04 ^b | | 0.27 ± 0.02 ^b | | 0.64 ± 0.09 ^a | | 0.87 ± 0.08 ^a | | <0.001 |
| Cecal pH | 6.87 ± 0.12 ^a | | 6.36 ± 0.08 ^b | | 6.36 ± 0.12 ^b | | 6.04 ± 0.06 ^b | | <0.001 |
| Acetic acid (μmol/g content) | 18.9 ± 1.5 ^{ab} | | 16.2 ± 1.2 ^b | | 23.8 ± 1.8 ^a | | 17.3 ± 1.9 ^b | | 0.012 |
| Propionic acid (μmol/g content) | 5.32 ± 0.55 ^a | | 1.82 ± 0.35 ^b | | 4.99 ± 0.33 ^a | | 4.14 ± 0.45 ^a | | <0.001 |
| n-Butyric acid (μmol/g content) | 1.17 ± 0.11 ^{ab} | | 0.54 ± 0.28 ^b | | 1.88 ± 0.33 ^a | | 1.06 ± 0.25 ^{ab} | | 0.011 |
| iso-Butyric acid (μmol/g content) | 2.06 ± 0.45 ^a | | 0.89 ± 0.18 ^{ab} | | 1.22 ± 0.35 ^{ab} | | 0.67 ± 0.14 ^b | | 0.025 |

680 The values are the means ± SE ($n = 7-8$). The values that do not share the same letter
 681 differ significantly between the treatments ($P < 0.05$, Tukey–Kramer test).

682 **Table 6. Body weight, visceral adipose tissue weight, and energy intake of rats fed**
 683 **test diets for 8 days.**

| | Control | | HFS | | HFS+RMD | | HFS+FOS | | ANOVA |
|-----------------------------------|---------|-------------------|--------|-------------------|---------|-------------------|---------|-------------------|---------|
| | Mean | SE | Mean | SE | Mean | SE | Mean | SE | P value |
| Initial body weight (g) | 169 ± | 2 | 172 ± | 3 | 171 ± | 2 | 169 ± | 2 | 0.723 |
| Final body weight (g) | 218 ± | 3 ^b | 237 ± | 5 ^a | 234 ± | 3 ^a | 225 ± | 4 ^{ab} | 0.008 |
| Body weight gain (g) | 49.0 ± | 1.1 ^c | 65.0 ± | 3.0 ^a | 63.1 ± | 2.4 ^{ab} | 56.0 ± | 1.9 ^{bc} | <0.001 |
| Visceral fat (g/100 g BW) | 2.89 ± | 0.16 ^b | 4.25 ± | 0.23 ^a | 3.50 ± | 0.12 ^b | 3.46 ± | 0.22 ^b | <0.001 |
| Light period energy intake (kcal) | 49.1 ± | 5.9 | 61.4 ± | 11.3 | 49.3 ± | 8.6 | 60.3 ± | 8.9 | 0.637 |
| Dark period energy Intake (kcal) | 520 ± | 13 ^b | 646 ± | 27 ^a | 588 ± | 11 ^{ab} | 549 ± | 21 ^b | 0.001 |
| Total energy intake (kcal) | 569 ± | 15 ^b | 708 ± | 22 ^a | 637 ± | 11 ^b | 609 ± | 19 ^b | <0.001 |

684 The values are the means ± SE ($n = 7-8$). The values that do not share the same letter
 685 differ significantly between the treatments ($P < 0.05$, Tukey–Kramer test).

686

687

688

689 **Table 7. Glucose, insulin, GLP-1, GIP, PYY levels and DPP-IV activity in portal**
 690 **plasma of rats fed test diets for 8 days.**

| | Control | | HFS | | HFS+RMD | | HFS+FOS | | ANOVA |
|-------------------|---------|-------------------|---------|--------------------|---------|--------------------|---------|-------------------|---------|
| | Mean | SE | Mean | SE | Mean | SE | Mean | SE | P value |
| Glucose (mg/dl) | 105.3 ± | 4.8 | 118.1 ± | 5.8 | 126.1 ± | 5.6 | 122.9 ± | 7.1 | 0.090 |
| Insulin (nM) | 0.7 ± | 0.1 | 1.1 ± | 0.1 | 1.0 ± | 0.1 | 0.9 ± | 0.1 | 0.152 |
| Total GLP-1 (pM) | 24.9 ± | 3.7 | 29.3 ± | 3.6 | 38.8 ± | 4.7 | 38.0 ± | 4.2 | 0.062 |
| Active GLP-1 (pM) | 7.2 ± | 1.3 | 13.4 ± | 2.0 | 15.9 ± | 4.4 | 14.4 ± | 1.9 | 0.141 |
| Total GIP (pM) | 1.8 ± | 0.5 | 3.7 ± | 1.1 | 2.6 ± | 1.1 | 2.6 ± | 0.7 | 0.567 |
| PYY (ng/mL) | 0.93 ± | 0.05 ^b | 0.97 ± | 0.07 ^{ab} | 1.09 ± | 0.04 ^{ab} | 1.18 ± | 0.08 ^a | 0.038 |
| DPP-IV (mU/mL) | 23.4 ± | 0.9 | 24.7 ± | 1.3 | 23.5 ± | 1.2 | 24.4 ± | 1.0 | 0.781 |

691 The values are the means ± SE ($n = 7-8$). The values that do not share the same letter
 692 differ significantly between the treatments ($P < 0.05$, Tukey–Kramer test).

693 **Table 8. Proglucagon mRNA expression in intestinal tissues of rats fed test diets for**
 694 **8 days.**

695

| Proglucagon/GAPDH (relative to Control) | Control | | HFS | | HFS+RMD | | HFS+FOS | | ANOVA |
|--|--------------------------|----|---------------------------|----|---------------------------|----|--------------------------|----|---------|
| | Mean | SE | Mean | SE | Mean | SE | Mean | SE | P value |
| Jejunum | 1.00 ± 0.22 | | 0.73 ± 0.13 | | 1.08 ± 0.17 | | 1.04 ± 0.17 | | 0.526 |
| Ileum | 1.00 ± 0.17 | | 0.49 ± 0.03 | | 0.58 ± 0.10 | | 0.62 ± 0.18 | | 0.078 |
| Cecum | 1.00 ± 0.07 ^a | | 0.81 ± 0.06 ^{ab} | | 0.88 ± 0.13 ^{ab} | | 0.64 ± 0.06 ^b | | 0.044 |
| Colon | 1.00 ± 0.15 | | 0.53 ± 0.08 | | 1.17 ± 0.18 | | 1.17 ± 0.27 | | 0.097 |

696 Total RNA was used for real-time PCR analysis. Proglucagon mRNA expression levels
 697 were normalized to that of GAPDH, and the data are expressed as relative changes
 698 compared to the control group. The values are the means ± SE ($n = 6-7$). The values that
 699 do not share the same letter differ significantly between the treatments ($P < 0.05$, Tukey–
 700 Kramer test).

701

702

703 **Table 9. Cecal tissue, content weights, pH and short chain fatty acid concentrations**
 704 **of rats fed test diets for 8 days.**

| | Control | | HFS | | HFS+RMD | | HFS+FOS | | ANOVA |
|-----------------------------------|--------------------------|----|---------------------------|----|--------------------------|----|---------------------------|----|---------|
| | Mean | SE | Mean | SE | Mean | SE | Mean | SE | P value |
| Cecal tissue (g/100 g BW) | 0.34 ± 0.03 ^b | | 0.29 ± 0.01 ^b | | 0.57 ± 0.02 ^a | | 0.56 ± 0.03 ^a | | <0.001 |
| Cecal content (g/100 g BW) | 1.07 ± 0.10 ^b | | 1.00 ± 0.09 ^b | | 2.40 ± 0.16 ^a | | 2.23 ± 0.15 ^a | | <0.001 |
| Cecal pH | 6.60 ± 0.21 ^a | | 6.27 ± 0.19 ^{ab} | | 5.86 ± 0.12 ^b | | 5.93 ± 0.19 ^{ab} | | 0.030 |
| Acetic acid (μmol/g content) | 16.5 ± 2.9 | | 19.2 ± 2.6 | | 16.3 ± 1.6 | | 20.9 ± 2.4 | | 0.494 |
| Propionic acid (μmol/g content) | 3.36 ± 0.51 ^b | | 2.81 ± 0.24 ^b | | 6.89 ± 0.62 ^a | | 6.27 ± 0.74 ^a | | <0.001 |
| n-Butyric acid (μmol/g content) | 1.40 ± 0.31 | | 3.37 ± 1.17 | | 4.28 ± 1.19 | | 4.31 ± 1.29 | | 0.223 |
| iso-Butyric acid (μmol/g content) | 1.58 ± 0.56 | | 2.75 ± 0.59 | | 0.79 ± 0.18 | | 0.58 ± 0.38 | | 0.092 |

705 The values are the means ± SE ($n = 6-7$). The values that do not share the same letter
 706 differ significantly between the treatments ($P < 0.05$, Tukey–Kramer test).

707 **Figure legends**

708 **Fig. 1. Plasma glucose, insulin, and GLP-1 levels measured by OGTTs after 4 and 7**
709 **weeks.**

710 OGTTs were performed in rats fasted overnight, after 4 weeks (A–C; oral glucose at 2
711 g/kg) and 7 weeks (D–F; oral glucose at 3 g/kg) of test diet feeding. Glucose solution was
712 orally administered at 0 min after the basal blood collection, and then blood samples were
713 collected from the tail vein over 120 min. Glucose (A, E), insulin (B, F), and total GLP-1 (C,
714 G) levels were measured in the plasma. The area under the curve (AUC) was calculated
715 using the trapezoidal rule. AUC of incremental HOMA-IR (D, H) was calculated by using
716 incremental AUC of glucose and insulin. The values are the means \pm SE ($n = 7-8$). Two-
717 way repeated ANOVA P values for time were all < 0.05 ; for treatment were all < 0.05 ; for
718 time \times treatment were A: 0.224, B: 0.754, C: 0.116, D: 0.792, E: 0.124, F: 0.949. The plots
719 that do not share the same letter differ significantly between the treatments at the same
720 time point ($P < 0.05$, Tukey–Kramer test). The bars that do not share the same letter differ
721 significantly between the treatments ($P < 0.05$, Tukey–Kramer test). n.s., no significant
722 difference among the treatments.

723
724 **Fig. 2. Weekly energy intake of rats fed test diets for 8 weeks.**

725 Rats were fed control diet, HFS diet, HFS diet supplemented with 5% RMD
726 (HFS+RMD), or HFS diet supplemented with 5% FOS (HFS+FOS) for 8 weeks, ad libitum.
727 The values are the means \pm SE ($n = 7-8$). Two-way repeated ANOVA P values for time
728 was < 0.001 ; for treatment was < 0.001 ; for time \times treatment was 0.085. The plots that do
729 not share the same letter differ significantly between the treatments at the same week ($P <$
730 0.05, Tukey–Kramer test).

731 **Fig. 3. GLP-1 content in intestinal tissues of rats fed test diets for 8 weeks.**

732 Intestinal tissues (cecum and colon) were separately collected after overnight fasting
733 from rats fed respective test diets (control, HFS, HFS+RMD, or HFS+FOS) for 8 weeks.
734 After acid–ethanol extraction, GLP-1 concentrations were measured, and the values were
735 corrected according to the tissue weight (pmol/g of tissue, A and B). GLP-1 contents in the
736 whole cecum (C) and colon (D) were calculated based on the whole tissue weights. The
737 values are the means \pm SE ($n = 7-8$). The bars that do not share the same letter differ
738 significantly between the treatments ($P < 0.05$, Tukey–Kramer test). n.s., no significant
739 difference among the treatments.

740

741 **Fig. 4. Energy intake by rats fed test diets for 8 days.**

742 Rats were fed control, HFS, HFS+RMD, or HFS+FOS diet for 8 days, ad libitum. Food
743 intake was measured at 08:00 a.m. and 20:00 p.m. every day. Energy intake was
744 calculated for the light period (A), for the dark period (B), and for the entire day (C). The
745 values are the means \pm SE ($n = 6-7$). Two-way repeated ANOVA P values for time were
746 all < 0.001 ; for treatment were A: 0.19, B and C: < 0.001 ; for time \times treatment were A:
747 0.592, B: 0.600, C: 0.934. The plots that do not share the same letter differ significantly
748 between the treatments on the same day ($P < 0.05$, Tukey–Kramer test).

749

750

751

752

753

754

755 **Fig. 5. GLP-1 content in intestinal tissues of rats fed test diets for 8 days.**


756 Intestinal tissues (cecum and colon) were separately collected after overnight fasting
757 from rats fed respective test diets (control, HFS, HFS+RMD, or HFS+FOS) for 8 days.
758 After acid–ethanol extraction, GLP-1 concentrations were measured, and the values were
759 corrected according to tissue weights (pmol/g of tissue, A and B). GLP-1 contents in the
760 whole cecum (C) and colon (D) were calculated based on the whole tissue weights. The
761 values are the means \pm SE ($n = 6-7$). The bars that do not share the same letter differ
762 significantly between the treatments ($P < 0.05$, Tukey–Kramer test). n.s., No significant
763 difference among the treatments.

764


765

OGTT, 4 wk


A



B



C



D




Fig. 1A-D

OGTT, 7 wk







Fig. 1E-H




Fig. 2




Fig. 3




Fig. 4




Fig. 5